AVN 67.54 No Change ▼ 0.00 (0%)
BOP 9.35 No Change ▼ 0.00 (0%)
CHCC 139.27 No Change ▼ 0.00 (0%)
DCL 10.89 No Change ▼ 0.00 (0%)
DGKC 112.94 No Change ▼ 0.00 (0%)
EFERT 66.44 No Change ▼ 0.00 (0%)
EPCL 45.64 No Change ▼ 0.00 (0%)
FCCL 20.50 No Change ▼ 0.00 (0%)
FFL 15.93 No Change ▼ 0.00 (0%)
HASCOL 15.78 No Change ▼ 0.00 (0%)
HBL 139.52 No Change ▼ 0.00 (0%)
HUBC 76.40 No Change ▼ 0.00 (0%)
HUMNL 8.09 No Change ▼ 0.00 (0%)
JSCL 27.18 No Change ▼ 0.00 (0%)
KAPCO 28.53 No Change ▼ 0.00 (0%)
KEL 3.89 No Change ▼ 0.00 (0%)
LOTCHEM 12.30 No Change ▼ 0.00 (0%)
MLCF 41.45 No Change ▼ 0.00 (0%)
OGDC 98.35 No Change ▼ 0.00 (0%)
PAEL 36.09 No Change ▼ 0.00 (0%)
PIBTL 13.27 No Change ▼ 0.00 (0%)
PIOC 98.87 No Change ▼ 0.00 (0%)
POWER 9.38 No Change ▼ 0.00 (0%)
PPL 86.77 No Change ▼ 0.00 (0%)
PSO 209.04 No Change ▼ 0.00 (0%)
SNGP 57.36 No Change ▼ 0.00 (0%)
STPL 12.67 No Change ▼ 0.00 (0%)
TRG 50.01 No Change ▼ 0.00 (0%)
UNITY 21.51 No Change ▼ 0.00 (0%)
COVID-19 TOTAL DAILY
CASES 327,063 847
DEATHS 6,727 12
Business

Roche says two-thirds of Evrysdi patients had got rival treatments

  • With now three drugs on the market in the last five years, SMA has become a very competitive.
  • Spinraza, Biogen's $2 billion per year seller that must be administered via spinal infusion about once every four months.
14 Sep 2020

ZURICH: Swiss drugmaker Roche on Monday said two-thirds of spinal muscular atrophy (SMA) patients now taking its newly approved drug Evrysdi have previously received rival treatments Zolgensma from Novartis or Biogen's Spinraza.

With now three drugs on the market in the last five years, SMA has become a very competitive, potentially very lucrative market.

Spinraza lists at $750,000 for the first year and $375,000 annually thereafter. Gene therapy Zolgensma at $2.1 million is the costliest one-time treatment, while Evrysdi, also called risdiplam, costs up to $340,000 per year.

Many analysts see Zolgensma as the option of choice, in particular for newborn babies diagnosed with SMA, since it is given by infusion a single time.

Spinraza, Biogen's $2 billion per year seller that must be administered via spinal infusion about once every four months, may face more direct competition from Roche's drug, which as a once-daily oral may have more convenient administration, analysts have said.

"We see patients with all types of SMA," Teresa Graham, Roche's head of pharma global product strategy, said on a call with investors about initial Evrysdi sales. "About 25% of patients have type 1 SMA...with about two-thirds of patients having prior experience with Spinraza or Zolgensma."

Evrysdi was approved last month. Roche, which partnered with PTC Therapeutics on the medicine, will likely give an update on initial Evrysdi sales in October.